

GA Clinical Trials

There are numerous clinical trials underway and in preparation for novel therapies for GA. The best source for information on clinical trials is clinicaltrials.gov

Table 1: Ongoing clinical studies of investigational agents in GA
(source: ClinicalTrials.gov – September 2017)

Drug	Mechanism of action	Method of administration	Sponsor	Clinical Phase	Study name / ClinicalTrials.gov Identifier	Estimated primary completion date
APL-2	Complement 3 (C3) inhibitor	Intravitreal injection	Apellis Pharmaceuticals	II	Filly NCT02503332	08/2017
CLG561 & tesidolumab	Properdin inhibitor & Complement 5 (C5) inhibitor	Intravitreal injection	Alcon Research	II	NCT02515942	09/2017
Lampalizumab	Complement 5 (C5) inhibitor	Intravitreal injection	Roche / Genentech	III	CHROMA NCT02247479	12/2017
Brimonidine	Alpha-2 adrenergic agonist (neuroprotection)	Intravitreal implant	Allergan	II	BEACON NCT02087085	09/2018
MA09-hRPE	Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (MA09-RPE) cells	Sub-retinal transplantation	Astellas Institute for Regenerative Medicine	I/II	NCT02463344	12/2019

GA Clinical Trials

Table 2: Planned clinical studies of investigational treatments in GA currently recruiting
(source: ClinicalTrials.gov – September 2017)

Treatment	Mechanism of action	Method of administration	Sponsor	Clinical Phase	ClinicalTrials.gov Identifier:	Estimated primary completion date
Minocycline	Microglial cell inhibition	Oral capsules	National Eye Institute (NEI)	II	NCT02564978	07/2021
Doxycycline (ORACEA®)	Anti-inflammatory	Oral capsules	MEDARVA Foundation	II/III	NCT01782989	07/2018
RO7171009	XXXXXX	Intravitreal injection	Roche/ Genentech	I	NCT03295877	10/2018
ARC1905 (Zimura®)	Complement 5 (C5) inhibitor	Intravitreal injection	Ophthotech Corporation	II/III	NCT02686658	12/2018
Metformin	Anti-oxidant; reduces reactive oxygen species levels to slow DNA damage	Oral tablets	University of California, San Francisco	II	METforMIN NCT02684578	04/2019
Alpha lipoic acid	Iron-chelating and antioxidant properties	Oral capsules	University of Pennsylvania	I/II	NCT02613572	05/2018
OpRegen	Human embryonic stem cell-derived RPE cells.	Sub-retinal transplantation	Cell Cure Neurosciences Ltd.	I/II	NCT02286089	09/2018
CNTO 2476	Human umbilical-tissue-derived cells	Sub-retinal transplantation	Janssen Research & Development, LLC	II	PRELUDE NCT02659098	12/2018
CPCB-RPE1	Human Embryonic Stem Cell-Derived RPE Cells	Sub-retinal transplantation	Regenerative Patch Technologies, LLC	I/II	NCT02590692	09/2018
AAVCAGsCD59	Gene therapy expressing C59 complement factor	Intravitreal injection	Hemera Biosciences	I	NCT03144999	10/2017
Nova Oculus™	BioCurrent Electrical Stimulation	Transpalpebral micro-current electrical stimulation	DuBois Vision Clinic	I/II	NCT02699216	12/2016